Aram Adourian - BG Medicine Insider

BGMD -- USA Stock  

USD 0.048  0.0179  59.47%

Chief Scientific Officer and Sr. VP
Dr. Aram Adourian, Ph.D., is Senior Vice President, Chief Scientific Officer of BG Medicine, Inc., since October 2012. Dr. Adourian worked as our Senior Director, Technology Assessment. In October 2003, Dr. Adourian was promoted to Vice President, Computational Sciences and served in such position until January 2007, when he was designated a general Vice President and served in such position until January 2009. In January 2009, Dr. Adourian was appointed as our Vice President, Scientific Affairs. In October 2012, Dr. Adourian was appointed as our Senior Vice President, Chief Scientific Officer. In May 2016, Dr. Adourian terminated his employment with the Company but he continues to serve as the Chief Scientific Officer of the Company on a consulting basis. Prior to joining us, Dr. Adourian worked at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology. While at MIT, Dr. Adourian served as Project Manager for Bioinformatics specializing in the development of novel systems and approaches for biomolecular sequencing, analysis and modeling
Age: 45  SVP Since 2012  Ph.D    
781-890-1199  http://www.bg-medicine.com
Adourian earned his Ph.D. at Harvard University in Statistical Physics, where he was a recipient of the Rudenberg Research Prize, and received his undergraduate degree in Physics from Cornell University.

Management Efficiency

The company has return on total asset (ROA) of (75.95) % which means that it has lost $75.95 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (902.64) % meaning that it created substantial loss on money invested by shareholders.

Entity Summary

BG Medicine, Inc. engages in development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts. BG Medicine operates under Diagnostics Research classification in USA and traded on OTC Market. It employs 5 people.BG Medicine (BGMD) is traded on OTC Market in USA. It is located in 303 Wyman Street and employs 5 people.

BG Medicine Leadership Team

James Connor, Director
Harry Wilcox, Director
Stelios Papadopoulos, Director, MBA
Aram Adourian, SVP, Ph.D
Stephen Hall, CFO, MBA
Jeffrey Luber, Director, MBA
Paul Sohmer, CEO
Noubar Afeyan, Founder
James OConnor, Director

Stock Performance Indicators

Did you try this?

Run Alpha Finder Now
   

Alpha Finder

Use alpha and beta coefficients to find investment opportunities after accounting for the risk
All  Next Launch Alpha Finder

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for BG Medicine and Advanced Accelerator. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Premium Stories module to follow macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.